March 2019 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017 and 2018/19 Invitation to Tender, dated 1 November 2018.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Furosemide [frusemide] |
Tab 40 mg, 1000 tablet pack |
$8.00 |
$7.24 |
Apo-Frusemide |
1 October 2019 |
1 December 2019 |
1 March 2020 |
Diurin 40 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Furosemide [frusemide] |
Tab 40 mg, 1000 tablet pack |
$8.00 |
$7.24 |
Apo-Frusemide |
1% |
1 October 2019 |
1 December 2019 |
Diurin 40 |
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Cefalexin |
Cap 250 mg, 20 capsule, blister pack |
$3.50 |
$3.33 |
Cephalexin ABM |
1 August 2019 |
1 November 2019 |
|
Chloramphenicol |
Eye drops 0.5%, 10 ml OP |
$1.95 |
$1.54 |
Chlorafast |
1 August 2019 |
1 November 2019 |
|
Dihydrocodeine tartrate |
Tab long-acting 60 mg, 60 tablet, bottle pack |
$9.55 |
$8.60 |
DHC Continus |
1 July 2019 |
1 October 2019 |
|
Iloprost |
Nebuliser soln 10 mcg per ml, 2 ml, 30 nebuliser pack |
$1,185.00 |
$740.10 |
Ventavis |
1 October 2019 |
1 January 2020 |
|
Intra-uterine device |
IUD 29.1 mm length x 23.2 mm width |
$31.60 |
$18.45 |
Choice TT380 Short |
1 August 2019 |
1 November 2019 |
|
Intra-uterine device |
IUD 33.6 mm length x 29.9 mm width |
$31.60 |
$18.45 |
Choice TT380 Standard |
1 August 2019 |
1 November 2019 |
|
Intra-uterine device |
IUD 35.5 mm length x 19.6 mm width |
$31.60 |
$15.50 |
Choice Load 375 |
1 August 2019 |
1 November 2019 |
|
Methadone hydrochloride |
Tab 5 mg,10 tablet, blister pack |
$1.85 |
$1.40 |
Methatabs |
1 June 2019 |
1 September 2019 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Sole supply brand (Supplier) |
Listing date |
Sole Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Amiodarone hydrochloride |
Inj 50 mg per ml, 3 ml ampoule, 10 pack |
$19.96 |
$16.37 |
Max Health |
1 August 2019 |
1 January 2020 |
Lodi Cordarone-X |
|
Compound hydroxybenzoate |
Soln, 100 ml bottle |
$30.00 |
$30.00 |
Midwest |
1 May 2019 |
1 August 2019 |
David Craig |
|
Montelukast |
Tab 4 mg, 28 tablet, blister pack |
$5.25 |
$4.25 |
Montelukast Mylan |
1 August 2019 |
1 January 2020 |
Apo-Montelukast |
|
Montelukast |
Tab 5 mg, 28 tablet, blister pack |
$5.50 |
$4.25 |
Montelukast Mylan |
1 August 2019 |
1 January 2020 |
Apo-Montelukast |
|
Montelukast |
Tab 10 mg, 28 tablet, blister pack |
$5.65 |
$3.95 |
Montelukast Mylan |
1 August 2019 |
1 January 2020 |
Apo-Montelukast Accord |
|
Temozolomide |
Cap 5 mg, 5 capsule, bottle pack |
$10.20 |
$9.13 |
Temaccord |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 20 mg, 5 capsule, bottle pack |
$18.30 |
$16.38 |
Temaccord |
1 December 2019 |
1 May 2020 |
Orion Temozolomide Temizole 20 |
|
Temozolomide |
Cap 100 mg, 5 capsule, bottle pack |
$40.20 |
$35.98 |
Temaccord |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 140 mg, 5 capsule, bottle pack |
$56.00 |
$50.12 |
Temaccord |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 250 mg, 5 capsule, bottle pack |
$96.80 |
$86.34 |
Temaccord |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Bupivacaine hydrochloride with adrenaline |
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial, 5 vial pack |
$135.00 |
$94.50 |
Marcain with Adrenaline |
1% |
1 May 2019 |
1 August 2019 |
|
Bupivacaine hydrochloride with adrenaline |
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial, 5 vial pack |
$115.00 |
$80.50 |
Marcain with Adrenaline |
1% |
1 May 2019 |
1 August 2019 |
|
Caspofungin |
Inj 50 mg vial, 1 vial pack |
$667.50 |
$220.28 |
Max Health |
1% |
1 July 2019 |
1 December 2019 |
|
Caspofungin |
Inj 70 mg vial, 1 vial pack |
$862.50 |
$284.63 |
Max Health |
1% |
1 July 2019 |
1 December 2019 |
|
Cefalexin |
Cap 250 mg, 20 capsule, blister pack |
$3.50 |
$3.33 |
Cephalexin ABM |
1% |
1 August 2019 |
1 November 2019 |
|
Chloramphenicol |
Eye drops 0.5%, 10 ml |
$1.95 |
$1.54 |
Chlorafast (Teva) |
1% |
1 August 2019 |
1 November 2019 |
|
Dihydrocodeine tartrate |
Tab long-acting 60 mg, 60 tablet, bottle pack |
$9.55 |
$8.60 |
DHC Continus |
1% |
1 July 2019 |
1 October 2019 |
|
Iloprost |
Nebuliser soln 10 mcg per ml, |
$1,185.00 |
$740.10 |
Ventavis |
1% |
1 October 2019 |
1 January 2020 |
|
Intra-uterine device |
IUD 29.1 mm length x 23.2 mm width |
$31.60 |
$18.45 |
Choice TT380 Short |
1% |
1 August 2019 |
1 November 2019 |
|
Intra-uterine device |
IUD 33.6 mm length x 29.9 mm width |
$31.60 |
$18.45 |
Choice TT380 Standard |
1% |
1 August 2019 |
1 November 2019 |
|
Intra-uterine device |
IUD 35.5 mm length x 19.6 mm width |
$31.60 |
$15.50 |
Choice Load 375 |
1% |
1 August 2019 |
1 November 2019 |
|
Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate |
powder for oral soln 59 g with |
$14.31 |
$14.31 |
Klean Prep |
1% |
1 May 2019 |
1 August 2019 |
|
Methadone hydrochloride |
Tab 5 mg. 10 tablet, blister pack |
$1.85 |
$1.40 |
Methatabs |
1% |
1 June 2019 |
1 September 2019 |
|
Sodium hyaluronate [Hyaluronic acid] |
Inj 14 mg per ml, 0.85 ml syringe, |
$50.00 |
$50.00 |
Healon GV |
1% |
1 July 2019 |
1 October 2019 |
|
Sodium hyaluronate [Hyaluronic acid] |
Inj 14 mg per ml, 0.55 ml syringe, |
$50.00 |
$50.00 |
Healon GV |
1% |
1 July 2019 |
1 October 2019 |
|
Sodium hyaluronate [Hyaluronic acid] |
Inj 23 mg per ml, 0.6 ml syringe, |
$60.00 |
$60.00 |
Healon 5 |
1% |
1 July 2019 |
1 October 2019 |
|
Sodium hyaluronate [Hyaluronic acid] |
Inj 10 mg per ml, 0.85 ml syringe, |
$28.50 |
$28.50 |
Healon |
1% |
1 July 2019 |
1 October 2019 |
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current price |
New pack price |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Amiodarone hydrochloride |
Inj 50 mg per ml, 3 ml ampoule, 10 pack |
$9.98 per 5 $11.98 per 6 |
$16.37 |
Max Health |
1% |
1 August 2019 |
1 January 2020 |
Lodi Cordaone-X |
|
Montelukast |
Tab 4 mg, 28 tablet, blister pack |
$5.25 |
$4.25 |
Montelukast Mylan |
1% |
1 August 2019 |
1 January 2020 |
Apo-Montelukast |
|
Montelukast |
Tab 5 mg, 28 tablet, blister pack |
$5.50 |
$4.25 |
Montelukast Mylan |
1% |
1 August 2019 |
1 January 2020 |
Apo-Montelukast |
|
Montelukast |
Tab 10 mg, 28 tablet, blister pack |
$5.65 |
$3.95 |
Montelukast Mylan |
1% |
1 August 2019 |
1 January 2020 |
Apo-Montelukast |
|
Temozolomide |
Cap 5 mg, 5 capsule, bottle pack |
$10.20 |
$9.13 |
Temaccord |
1% |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 20 mg, 5 capsule, bottle pack |
$18.30 |
$16.38 |
Temaccord |
1% |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 100 mg, 5 capsule, bottle pack |
$40.20 |
$35.98 |
Temaccord |
1% |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
|
Temozolomide |
Cap 250 mg, 5 capsule, bottle pack |
$96.80 |
$86.34 |
Temaccord |
1% |
1 December 2019 |
1 May 2020 |
Orion Temozolomide |
7. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Compound hydroxybenzoate |
Soln, 100 ml bottle |
$30.00 |
Midwest |
1% |
1 May 2019 |
1 August 2019 |
|
Temozolomide |
Cap 140 mg, 5 capsule, bottle pack |
$50.12 |
Temaccord |
1% |
1 December 2019 |
1 May 2020 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2018/19 Invitation to Tender, dated 1 November 2018
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Ajmaline |
Inj 50 mg per 10 ml |
|
Aluminium hydroxide with magnesium |
Oral liq 400 mg with magnesium hydroxide 400 mg and |
|
Aluminium hydroxide with magnesium |
Tab 200 mg with magnesium hydroxide 200 mg and |
|
Ascorbic acid |
Tab (chewable) 250 mg |
|
Bee venom allergy treatment |
Maintenance kit – 6 vials 120 mcg freeze dried venom |
|
Bee venom allergy treatment |
Treatment kit – 1 vial 550 mcg freeze dried venom, 1 |
|
Betamethasone |
Inj 4 mg per ml, 1 ml |
|
Betamethasone |
Tab 500 mcg |
|
Candesartan cilexetil with |
Tab 16 mg with hydrochlorothiazide 12.5 mg |
|
Candesartan cilexetil with |
Tab 32 mg with hydrochlorothiazide 12.5 mg |
|
Candesartan cilexetil with |
Tab 32 mg with hydrochlorothiazide 25 mg |
|
Carboxymethylcellulose |
Oral spray |
|
Cilazapril with hydrochlorothiazide |
Tab 5 mg with hydrochlorothiazide 12.5 mg |
|
Clobetasone butyrate |
Crm 0.05% (pack size 30 g or less) |
|
Dexamethasone |
Eye drops 0.1% |
|
Dexamethasone |
Eye oint 0.1% |
|
Dichlorobenzyl alcohol with |
Lozenge 1.2 mg with amylmetacresol 0.6 mg |
|
Digoxin |
Oral liq 50 mcg per ml |
|
Docusate sodium |
Ear drops 0.5% |
|
Erythromycin Stearate |
Tab 250 mg |
|
Erythromycin Stearate |
Tab 500 mg |
|
Etoposide |
Inj 20 mg per ml, 5 ml |
|
Fluocortolone caproate with |
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g |
|
Fluocortolone caproate with |
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, |
|
Gentamicin Sulphate |
Eye drops 0.3% |
|
Hydrocortisone with Cinchocaine |
Oint 5 mg with cinchocaine hydrochloride 5 mg per g |
|
Hydrocortisone with Cinchocaine |
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g |
|
Ketoprofen |
Cap long-acting 200 mg |
|
Lidocaine [Lignocaine] hydrochloride |
Inj 1%, 5 ml |
|
Macrogol 3350 |
Powder for oral soln |
|
Macrogol 3350 with potassium chloride, |
Powder for oral soln 6.563 g with potassium chloride |
|
Meloxicam [current access] |
Tab 7.5 mg |
|
Meloxicam [widened access] |
Tab 7.5 mg |
|
Methylprednisolone aceponate |
Oint 0.1% |
|
Mupirocin (pack size 5 g or less) |
Oint 2% |
|
Pericyazine |
Tab 10 mg |
|
Pericyazine |
Tab 2.5 mg |
|
Phentolamine Mesylate |
Inj 10 mg per ml, 1 ml |
|
Podophyllotoxin |
Soln 0.5% |
|
Prochlorperazine |
Tab 3 mg buccal |
|
Propranolol |
Cap long-acting 160 mg |
|
Propranolol |
Inj 1 mg per ml, 1 ml |
|
Propranolol |
Oral liq 4 mg per ml |
|
Pseudoephedrine Hydrochloride |
Tab 60 mg |
|
Retinol |
Cap 25,000 iu |
|
Retinol |
Oral liq 150,000 iu per ml |
|
Retinol |
Tab 10,000 iu |
|
Rifabutin |
Cap 150 mg |
|
Sildenafil |
Inj 0.8 mg per ml, 12.5 ml vial |
|
Sodium cromoglicate |
Cap 100 mg |
|
Sodium cromoglicate |
Nasal spray, 4% |
|
Spiramycin |
Tab 500 mg |
|
Tetracosactide [Tetracosactrin] |
Inj 1 mg per ml, 1 ml |
|
Tetracosactide [Tetracosactrin] |
Inj 250 mcg per ml, 1 ml |
|
Ticagrelor |
Tab 90 mg |
|
Yellow jacket wasp venom |
Inj 550 mcg vial with diluent |
|
Yellow jacket wasp venom |
Treatment kit – 6 vials 120 mcg freeze dried venom with |
|
Zuclopenthixol hydrochloride |
Tab 10 mg |
For products included in the 2016/17, 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.